Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block
NCT ID: NCT03328299
Last Updated: 2020-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
24 participants
INTERVENTIONAL
2017-11-11
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Two Doses of Dexmedetomidine as Adjuvent to Bupivacaine in Tap Block
NCT06624319
Dexmedetomidine Versus Fentanyl Added to Levobupivacaine for Transversus Abdominis Plane (TAP) Block
NCT03778671
Dexmedetomine vs Dexamethasone in TAB Block for Abdominal Surgries
NCT05323565
Dexmedetomidine Versus Clonidine in TAP Block
NCT03155646
Dexmedetomidine in Postoperative Analgesia
NCT05705128
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexmedetomidine group
patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
Dexmedetomidine
20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
bupivacaine group
patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
bupivacaine
20 ml of 0.5 % bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
bupivacaine
20 ml of 0.5 % bupivacaine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients (age 18-60 years
* weight 50-89 kg
Exclusion Criteria
* significant cardiac
* respiratory, renal or hepatic diseases
* bleeding diathesis
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatma Adel El sherif,MD
lecturer of anesthesia , ICU and pain management
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
South Egypt Cancer instIitute
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
El Sherif FA, Abdel-Ghaffar H, Othman A, Mohamed S, Omran M, Shouman S, Hassan N, Allam A, Hassan S. Pharmacokinetics and Pharmacodynamics of Dexmedetomidine Administered as an Adjunct to Bupivacaine for Transversus Abdominis Plane Block in Patients Undergoing Lower Abdominal Cancer Surgery. J Pain Res. 2022 Jan 4;15:1-12. doi: 10.2147/JPR.S335806. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.